Monday, August 9, 2010

Top 10 Fastest-Growing Pharmaceutical Stocks: CPIX, AMLN, AVNR, VVUS, BJGP, SLXP, LCI, ALXN, BMRN, MYGN (Aug 09, 2010)

Below are the top 10 fastest-growing Pharmaceutical stocks, based on the average long-term earnings growth rate estimated by Wall Street analysts. One Chinese company (BJGP) is on the list.
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) is the 1st fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 75.0%. This number is based on the average estimate of 1 brokerage analyst(s). Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) is the 2nd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 57.3%. This number is based on the average estimate of 2 brokerage analyst(s). AVANIR Pharmaceuticals (NASDAQ:AVNR) is the 3rd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 56.0%. This number is based on the average estimate of 1 brokerage analyst(s). VIVUS, Inc. (NASDAQ:VVUS) is the 4th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 54.2%. This number is based on the average estimate of 1 brokerage analyst(s). BMP Sunstone Corp. (NASDAQ:BJGP) is the 5th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 47.0%. This number is based on the average estimate of 1 brokerage analyst(s).
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) is the 6th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 42.5%. This number is based on the average estimate of 2 brokerage analyst(s). Lannett Company, Inc. (AMEX:LCI) is the 7th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 34.0%. This number is based on the average estimate of 1 brokerage analyst(s). Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is the 8th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 32.2%. This number is based on the average estimate of 9 brokerage analyst(s).BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is the 9th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 31.4%. This number is based on the average estimate of 2 brokerage analyst(s). Myriad Genetics, Inc. (NASDAQ:MYGN) is the 10th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 31.3%. This number is based on the average estimate of 7 brokerage analyst(s).
source:cnanalyst

No comments: